Can Erectile Dysfunction Drugs Reduce Dementia Risk? – Medpage Today

by Judy George, Deputy Managing Editor, MedPage Today
New research failed to support the hypothesis that phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) and tadalafil (Cialis) are promising drug repurposing candidates for Alzheimer’s disease and dementia.
Using four analytic approaches designed to address potential biases, PDE5 inhibitors did not reduce the risk of Alzheimer’s and related dementia compared with other drugs used for pulmonary arterial hypertension (PAH), showed Rishi Desai, MS, PhD, of Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues.
The findings, published in Brain Communications, are part of the ongoing NIH DREAM (Drug Repurposing for Effective Alzheimer’s Medicines) initiative.
PDE5 inhibitors work by relaxing smooth muscle cells. Sildenafil and tadalafil are approved treatments for erectile dysfunction and PAH.
The new DREAM study findings conflict with a recent analysis in Nature Aging that suggested sildenafil users were 69% less likely to develop Alzheimer’s disease than non-sildenafil users.
“Major differences in the design of these two investigations likely explain this inconsistency,” co-author Madhav Thambisetty, MD, PhD, of the National Institute on Aging, told MedPage Today.
In the Nature Aging analysis, Feixiong Cheng, PhD, of the Cleveland Clinic Genomic Medicine Institute, and colleagues compared the risk of incident Alzheimer’s disease in sildenafil users against people who used antihypertensive agents or type 2 diabetes drugs.
“This design choice is likely to result in comparison of individuals with erectile dysfunction — which is by far the most common indication for sildenafil — to generally older individuals with diabetes or hypertension,” Thambisetty observed.
“Since worse cardiometabolic health is a well-recognized risk factor for Alzheimer’s disease, and seeking treatment for erectile dysfunction is likely reflective of a certain level of preserved physical and cognitive function, we believe that results from [Cheng’s group] can be at least partly explained by severe confounding by indication,” he pointed out.
“We restricted our analyses to an alternative indication for PDE5 inhibitors — PAH — and selected an equivalent comparator drug that is used for the same indication to minimize confounding by indication,” Thambisetty stated.
In rodents, sildenafil has been shown to improve memory and cognitive function, help synaptic plasticity and learning, and reduce amyloid burden. Tadalafil also has improved memory and learning and lowered amyloid in rodents. “However, results in human studies have been inconsistent,” Desai and colleagues noted.
Using Medicare fee-for-service claims data from 2007 through 2018, DREAM study researchers matched 2,888 patients with PAH on PDE5 inhibitors (73.6% sildenafil, 26.4% tadalafil) with 2,888 comparable people on endothelin receptor antagonists.
Mean age of the cohort was 74, and 69% were women. Overall, 90% had hypertension, 72% had heart failure, and 43% had atrial fibrillation.
The research group used four analytic approaches to counter possible biases like informative censoring, reverse causality, and outcome misclassification:
In all four analyses, PDE5 inhibitors were not associated with reduced risk for Alzheimer’s and dementia. Hazard ratios were 0.99 (95% CI 0.69–1.43), 1.00 (95% CI 0.71–1.42), 0.67 (95% CI 0.43–1.06), and 1.15 (95% CI 0.57–2.34), respectively.
The researchers also tested whether sildenafil had effects on cell culture-based Alzheimer’s models and found no evidence that the drug corrected molecular abnormalities associated with Alzheimer’s disease.
The study may have been underpowered to detect differences of small magnitude, Desai and colleagues noted. Evaluating people with PAH allowed for unbiased comparisons of treatment effects, but this population is atypical with a high underlying cardiometabolic disease burden, they acknowledged.
Nonetheless, “electronic health records in large real-world clinical datasets are important tools to test hypotheses about plausible drug targets in Alzheimer’s disease and related dementias,” Thambisetty said.
Previous results from the DREAM initiative have shown that tumor necrosis factor inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer’s and dementia in people with cardiovascular disease.
Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow
Disclosures
The DREAM study is funded by the intramural program of the National Institute on Aging.
Desai disclosed relationships with Bayer, Vertex, and Novartis. Co-authors dislcosed relationships with Bristol-Myers Squibb, Merck, Pfizer, Lilly, Intra-Cellular Therapies, Eisai, Boehringer Ingelheim, Aetion, Roche, AbbVie, Danisco, and Med Tech Epi.
Primary Source
Brain Communications
Source Reference: Desai RJ et al “No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: Results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study” Brain Commun 2022; DOI: 10.1093/braincomms/fcac247.
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
© 2022 MedPage Today, LLC. All rights reserved.
Medpage Today is among the federally registered trademarks of MedPage Today, LLC and may not be used by third parties without explicit permission.

source

Add a Comment

Your email address will not be published. Required fields are marked *